Clinical Trial

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

Study acronym: OASIS
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-06 -> 2026-10-30 2026-08-12
Trial Details
NCT Number NCT05705414
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: National Center for Advancing Translational Sciences (NCATS), IIMS-UT Health San Antonio
Conditions End Stage Renal Disease
Enrollment 28 participants
Start Date 2024-10-18
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-11